Participant outcomes
| Baseline mean (SD) | 6 Months mean (SD) | 12 Months mean (SD) | |
| Secondary outcome evaluation | |||
| UPDRS Part III (OFF medication)* | 38.5 (11.4) | N/A | N/A |
| UPDRS Part III (OFF medication/OFF stimulation)* | N/A | 30.5 (12.9)† | 30.9 (9.9)† |
| Modified Hoehn & Yahr (OFF-state)‡ | 3.0 (0.7) | 2.5 (0.4) | 2.6 (0.7) |
| Combined therapy evaluation | |||
| UPDRS Part I§ | 3.4 (2.2) | 3.1 (2.8) | 3.5 (2.1) |
| UPDRS Part II¶ | 18.3 (6.7) | 13.3 (5.6) | 13.9 (5.8) |
| UPDRS Part III (ON medication)** | 18.3 (9.4) | N/A | N/A |
| UPDRS Part III (ON medication/ON stimulation)** | N/A | 15.4 (6.4) | 14.3 (6.2) |
| Complications of therapy evaluation | |||
| UPDRS Part IV†† | 6.8 (3.2) | 3.1 (2.0) | 3.1 (2.1) |
| Dyskinesia items 32, 33, 34 | 1.9 (2.2) | 0.2 (0.6) | 0.1 (0.3) |
| Modified Hoehn & Yahr (ON-state)‡‡ | 2.1 (0.5) | 2.1 (0.5) | 2.2 (0.4) |
For all scales, higher scores indicate more severe parkinsonism.
*Motor examination while off therapy (range 0–108).
†P=0.002 main effect of time. Significant decrease at 6 months and 12 months versus baseline.
‡Measured while off therapy (range 0–5).
§Mentation, behaviour and mood (range 0–16).
¶Activities of daily living while on therapy (range 0–52).
**Motor examination while on therapy (range 0–108).
††Complications of therapy (range 0–23).
‡‡Measured while on therapy (range 0–5).
UPDRS, Unified Parkinson’s Disease Rating Scale.